Clinician answer page

Deprescribing after cancer treatment

Most survivors leave treatment carrying a medication list built for a phase of care that has ended. This page answers the question the gap map keeps surfacing: which of those drugs to stop, which to keep, how fast to taper, and what to watch while you do it.

A five-step medication review at survivorship entry

1. Rebuild the list at survivorship entry
Reconcile every prescription, over-the-counter product, and supplement against a current indication. Anything started during treatment gets an explicit keep-or-stop decision recorded once, not deferred at each visit.
2. Separate cardioprotective from supportive-care drugs
Supportive-care agents (antiemetics, PPIs, sedatives) are the deprescribing targets. Cardioprotective therapy started after a documented LVEF decline usually stays, because withdrawal is a known trigger for recurrent dysfunction.
3. Change one drug at a time
Sequential single changes keep attribution clean. Simultaneous taper of two sedating agents makes any new symptom uninterpretable.
4. Give the survivor the plan in writing
A one-page taper schedule with what to expect, what is normal, and when to call prevents the silent restart that undoes most deprescribing.
5. Book the review before the taper starts
A scheduled 4 to 6 week check converts a taper into a monitored intervention. Without it, the default outcome is an unrecorded resumption at full dose.

Drug-by-drug: stop, keep, and how to taper

Proton pump inhibitors started during treatment

Why it is still on the list: Begun for chemotherapy-related dyspepsia or steroid cover and rarely revisited.
Keep when: Barrett esophagus, documented erosive esophagitis, ongoing high-dose steroids or NSAIDs.
Taper: Halve the dose for 2 to 4 weeks, then move to on-demand dosing; expect transient rebound acid symptoms.
Watch: Recurrent reflux, dysphagia, weight loss. Long-term use is associated with hypomagnesemia and B12 depletion.

Antiemetics (prochlorperazine, metoclopramide, olanzapine)

Why it is still on the list: Prescribed cycle by cycle and often left on the list years after the last infusion.
Keep when: Active gastroparesis or ongoing emetogenic therapy.
Taper: Stop outright once therapy has ended and nausea has resolved; no taper needed for as-needed dosing.
Watch: Extrapyramidal symptoms and tardive dyskinesia with metoclopramide and prochlorperazine argue for early stopping.

Opioids continued past the treatment phase

Why it is still on the list: Started for mucositis, post-surgical, or procedural pain; continued without a pain diagnosis.
Keep when: Persistent cancer-related pain, chronic post-surgical or neuropathic pain with a documented functional benefit.
Taper: Reduce 10 percent of the total daily dose every 1 to 2 weeks in stable survivors; slower after long-term use.
Watch: Function, not just pain score. Screen for withdrawal, mood change, and untreated neuropathic pain that needs a different agent.

Benzodiazepines and Z-drugs for scan anxiety or insomnia

Why it is still on the list: Intended for a single scan or a bad week, then refilled.
Keep when: Rarely; a short course tied to a specific procedure is reasonable.
Taper: Reduce 10 to 25 percent every 2 weeks, slower at the end; pair with CBT-I for insomnia.
Watch: Falls, cognitive fog that can be mistaken for cancer-related cognitive impairment, and rebound insomnia.

Bisphosphonates given for treatment-induced bone loss

Why it is still on the list: Started during aromatase-inhibitor or androgen-deprivation therapy and continued indefinitely.
Keep when: Ongoing endocrine therapy, prior fragility fracture, or persistent osteoporotic T-score.
Taper: Consider a drug holiday after 3 to 5 years in survivors no longer on bone-toxic therapy, with DXA at holiday start.
Watch: Fracture risk recalculated at each holiday review; atypical femoral pain and jaw symptoms.

Statins and antihypertensives added during cardiotoxicity monitoring

Why it is still on the list: Started as cardioprotection during anthracycline or HER2-directed therapy.
Keep when: Recovered or persistent cardiomyopathy, established ASCVD risk, ongoing chest-radiation late effects.
Taper: Usually do not stop. Continue guideline-directed therapy in anyone with a prior LVEF drop, even after recovery.
Watch: LVEF and symptoms after any dose reduction; recurrence of dysfunction is common when therapy is withdrawn.

Antidepressants started at diagnosis

Why it is still on the list: Prescribed during the acute phase and never reassessed at survivorship entry.
Keep when: Recurrent depression, ongoing anxiety, hot-flash control with venlafaxine, neuropathic pain with duloxetine.
Taper: After at least 6 to 12 months of remission, reduce over 4 or more weeks; longer for paroxetine and venlafaxine.
Watch: Discontinuation symptoms, relapse in the first 3 months, and CYP2D6 interaction with tamoxifen for some SSRIs.

Supplements and antioxidant stacks

Why it is still on the list: Started independently during treatment; frequently absent from the medication list.
Keep when: Documented deficiency, calcium and vitamin D where bone health requires it.
Taper: Stop what has no indication; reconcile with the survivor rather than for them.
Watch: St John's wort, high-dose antioxidants, and grapefruit-class interactions with endocrine and targeted therapy.

Medication	Why it persists	Keep when	Taper	Watch
Proton pump inhibitors started during treatment	Begun for chemotherapy-related dyspepsia or steroid cover and rarely revisited.	Barrett esophagus, documented erosive esophagitis, ongoing high-dose steroids or NSAIDs.	Halve the dose for 2 to 4 weeks, then move to on-demand dosing; expect transient rebound acid symptoms.	Recurrent reflux, dysphagia, weight loss. Long-term use is associated with hypomagnesemia and B12 depletion.
Antiemetics (prochlorperazine, metoclopramide, olanzapine)	Prescribed cycle by cycle and often left on the list years after the last infusion.	Active gastroparesis or ongoing emetogenic therapy.	Stop outright once therapy has ended and nausea has resolved; no taper needed for as-needed dosing.	Extrapyramidal symptoms and tardive dyskinesia with metoclopramide and prochlorperazine argue for early stopping.
Opioids continued past the treatment phase	Started for mucositis, post-surgical, or procedural pain; continued without a pain diagnosis.	Persistent cancer-related pain, chronic post-surgical or neuropathic pain with a documented functional benefit.	Reduce 10 percent of the total daily dose every 1 to 2 weeks in stable survivors; slower after long-term use.	Function, not just pain score. Screen for withdrawal, mood change, and untreated neuropathic pain that needs a different agent.
Benzodiazepines and Z-drugs for scan anxiety or insomnia	Intended for a single scan or a bad week, then refilled.	Rarely; a short course tied to a specific procedure is reasonable.	Reduce 10 to 25 percent every 2 weeks, slower at the end; pair with CBT-I for insomnia.	Falls, cognitive fog that can be mistaken for cancer-related cognitive impairment, and rebound insomnia.
Bisphosphonates given for treatment-induced bone loss	Started during aromatase-inhibitor or androgen-deprivation therapy and continued indefinitely.	Ongoing endocrine therapy, prior fragility fracture, or persistent osteoporotic T-score.	Consider a drug holiday after 3 to 5 years in survivors no longer on bone-toxic therapy, with DXA at holiday start.	Fracture risk recalculated at each holiday review; atypical femoral pain and jaw symptoms.
Statins and antihypertensives added during cardiotoxicity monitoring	Started as cardioprotection during anthracycline or HER2-directed therapy.	Recovered or persistent cardiomyopathy, established ASCVD risk, ongoing chest-radiation late effects.	Usually do not stop. Continue guideline-directed therapy in anyone with a prior LVEF drop, even after recovery.	LVEF and symptoms after any dose reduction; recurrence of dysfunction is common when therapy is withdrawn.
Antidepressants started at diagnosis	Prescribed during the acute phase and never reassessed at survivorship entry.	Recurrent depression, ongoing anxiety, hot-flash control with venlafaxine, neuropathic pain with duloxetine.	After at least 6 to 12 months of remission, reduce over 4 or more weeks; longer for paroxetine and venlafaxine.	Discontinuation symptoms, relapse in the first 3 months, and CYP2D6 interaction with tamoxifen for some SSRIs.
Supplements and antioxidant stacks	Started independently during treatment; frequently absent from the medication list.	Documented deficiency, calcium and vitamin D where bone health requires it.	Stop what has no indication; reconcile with the survivor rather than for them.	St John's wort, high-dose antioxidants, and grapefruit-class interactions with endocrine and targeted therapy.

Questions clinicians ask about deprescribing in survivorship

When is the right time to deprescribe after cancer treatment?

At entry to survivorship, once acute treatment toxicity has resolved and the survivor is clinically stable, typically 3 to 6 months after the last treatment. Waiting for a problem to appear means the medication list has already been carried for years.

Should cardioprotective medication started during chemotherapy be stopped?

Usually not. Beta blockers, ACE inhibitors or ARBs, and statins begun after a documented LVEF decline should generally continue as guideline-directed therapy. Recurrent dysfunction after withdrawal is well described, so any reduction needs echocardiographic follow-up.

Who owns deprescribing, oncology or primary care?

Primary care is best placed to run the taper, but the keep-or-stop decision for cardioprotective and endocrine agents belongs with oncology or cardio-oncology. Documenting the split in a shared-care plan is what prevents the drug from being carried by default.

How fast can opioids be tapered in a stable survivor?

A reduction of about 10 percent of the total daily dose every 1 to 2 weeks is tolerated by most stable survivors. Longer exposure warrants slower reduction, and function rather than the pain score should drive the pace.

Where to go next

Deprescribing worksheet

Run the review as a structured tool, without entering PHI.

Surveillance schedules by exposure

What to watch, how often, and the guideline behind it.

Who owns what

Split the keep-or-stop decision across oncology and primary care.

Back to the gap map

The full index of survivorship questions and where they are answered.

Nothing on this page requires a login or a chart pull. Privacy questions are answered on the privacy FAQ.